Ronan Chaligne
Overview
Explore the profile of Ronan Chaligne including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
1606
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fu Y, Land M, Kavlashvili T, Cui R, Kim M, DeBitetto E, et al.
Cell
. 2025 Mar;
PMID: 40068680
Recent breakthroughs in the genetic manipulation of mitochondrial DNA (mtDNA) have enabled precise base substitutions and the efficient elimination of genomes carrying pathogenic mutations. However, reconstituting mtDNA deletions linked to...
2.
Moorman A, Benitez E, Cambuli F, Jiang Q, Mahmoud A, Lumish M, et al.
Nature
. 2025 Jan;
637(8047):E28.
PMID: 39789339
No abstract available.
3.
Abay T, Stickels R, Takizawa M, Nalbant B, Hsieh Y, Hwang S, et al.
Nat Genet
. 2025 Jan;
57(2):451-460.
PMID: 39779958
Single-cell genomics technologies have accelerated our understanding of cell-state heterogeneity in diverse contexts. Although single-cell RNA sequencing identifies rare populations that express specific marker transcript combinations, traditional flow sorting requires...
4.
Zhuang X, Wang Q, Joost S, Ferrena A, Humphreys D, Li Z, et al.
Nature
. 2024 Dec;
637(8044):184-194.
PMID: 39633048
Ageing is associated with a decline in the number and fitness of adult stem cells. Ageing-associated loss of stemness is posited to suppress tumorigenesis, but this hypothesis has not been...
5.
Moorman A, Moorman A, Benitez E, Benitez E, Cambuli F, Cambulli F, et al.
Nature
. 2024 Oct;
637(8047):947-954.
PMID: 39478232
As cancers progress, they become increasingly aggressive-metastatic tumours are less responsive to first-line therapies than primary tumours, they acquire resistance to successive therapies and eventually cause death. Mutations are largely...
6.
Sango J, Carcamo S, Sirenko M, Maiti A, Mansour H, Ulukaya G, et al.
Nature
. 2024 Oct;
636(8041):241-250.
PMID: 39478230
Cancer driver mutations often show distinct temporal acquisition patterns, but the biological basis for this, if any, remains unknown. RAS mutations occur invariably late in the course of acute myeloid...
7.
Fu Y, Land M, Cui R, Kavlashvili T, Kim M, Lieber T, et al.
bioRxiv
. 2024 Oct;
PMID: 39463974
Highlights: Combining prokaryotic end-joining with targeted endonucleases generates specific mtDNA deletions in human cellsEngineering a panel of cell lines with a large-scale deletion that spans the full spectrum of heteroplasmy75%...
8.
Romero R, Chu T, Gonzalez Robles T, Smith P, Xie Y, Kaur H, et al.
Nat Cancer
. 2024 Oct;
5(11):1641-1659.
PMID: 39394434
Lineage plasticity is a hallmark of cancer progression that impacts therapy outcomes, yet the mechanisms mediating this process remain unclear. Here, we introduce a versatile in vivo platform to interrogate...
9.
Zhuang X, Wang Q, Joost S, Ferrena A, Humphreys D, Li Z, et al.
bioRxiv
. 2024 Jul;
PMID: 38979280
Aging is associated with a decline in the number and fitness of adult stem cells . Aging-associated loss of stemness is posited to suppress tumorigenesis , but this hypothesis has...
10.
Zaidi S, Park J, Chan J, Roudier M, Zhao J, Gopalan A, et al.
Proc Natl Acad Sci U S A
. 2024 Jul;
121(28):e2322203121.
PMID: 38968122
Targeting cell surface molecules using radioligand and antibody-based therapies has yielded considerable success across cancers. However, it remains unclear how the expression of putative lineage markers, particularly cell surface molecules,...